FULGENT GENETICS, INC. Debt Securities, Available-for-sale, Unrealized Loss
FULGENT GENETICS, INC. (FLGT) reported Debt Securities, Available-for-sale, Unrealized Loss of $298.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2021-03-08
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2020-12-31 was $298.00K, a 861.29% increase year-over-year.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2020-09-30 was -$6.00K.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2020-06-30 was -$363.00K.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2020-03-31 was $369.00K, a 738.64% increase year-over-year.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized loss for fiscal 2020 was $298.00K, a 831.25% increase from fiscal 2019.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized loss for fiscal 2019 was $32.00K, a 69.23% decline from fiscal 2018.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized loss for fiscal 2018 was $104.00K, a 36.59% decline from fiscal 2017.
- FULGENT GENETICS, INC. debt securities, available-for-sale, unrealized loss for fiscal 2017 was $164.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2020-12-31 | $298.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $292.00K derived: sum of 2 quarters · filed 2021-03-08 | -$71.00K derived: sum of 3 quarters · filed 2021-03-08 | $298.00K 10-K · filed 2021-03-08 |
| 2020-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$369.00K derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | $31.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2020-06-30 | -$363.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $6.00K 10-Q · filed 2020-08-05 | $37.00K derived: sum of 3 quarters · filed 2021-03-08 | $25.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2020-03-31 | $369.00K 10-Q · filed 2020-05-06 | $400.00K derived: sum of 2 quarters · filed 2021-03-08 | $388.00K derived: sum of 3 quarters · filed 2021-03-08 | $357.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $19.00K derived: sum of 2 quarters · filed 2021-03-08 | -$12.00K derived: sum of 3 quarters · filed 2021-03-08 | $32.00K 10-K · filed 2021-03-08 |
| 2019-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$43.00K derived: sum of 2 quarters · filed 2019-11-08 | $1.00K 10-Q · filed 2019-11-08 | -$18.00K derived: sum of 4 quarters · filed 2020-03-13 |
| 2019-06-30 | -$31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $13.00K 10-Q · filed 2019-08-12 | -$6.00K derived: sum of 3 quarters · filed 2020-03-13 | |
| 2019-03-31 | $44.00K 10-Q · filed 2019-05-10 | $25.00K derived: sum of 2 quarters · filed 2020-03-13 | ||
| 2018-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $104.00K 10-K · filed 2020-03-13 | ||
| 2018-09-30 | $123.00K 10-Q · filed 2018-11-09 | |||
| 2018-03-31 | $104.00K 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $164.00K 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |